Սաուդյան Արաբիա - անգլերեն - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

glaxo saudi arabia ltd., saudi arabia - lamivudine - solution - 10 mg/ml

Սաուդյան Արաբիա - անգլերեն - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

glaxo saudi arabia ltd., saudi arabia - lamivudine - oral solution - 10 mg/ml

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

chartwell rx, llc - lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95) - lamivudine oral solution, usp is a nucleoside analogue indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (hiv-1) infection. limitations of use: -  the dosage of this product is for hiv-1 and not for hbv. lamivudine oral solution is contraindicated in patients with a previous hypersensitivity reaction to lamivudine. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to lamivudine during pregnancy. healthcare providers are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1-800-258-4263.  risk summary available data from the apr show no difference in the overall risk of birth defects for lamivudine compared with the background rate for birth defects of 2.7% in the metropolitan atlanta congenital defects program (macdp) reference population (see data) . the apr uses the macdp as the u.s. reference population for birth defects in the general

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

remedyrepack inc. - lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95) - lamivudine 300 mg

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

avera mckennan hospital - lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95) - lamivudine 150 mg

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

kaiser foundation hospitals - lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95) - lamivudine 100 mg

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

remedyrepack inc. - lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95) - lamivudine tablet is a nucleoside analogue indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (hiv-l) infection.   limitation of use: the dosage of this product is for hiv-1and not for hbv. lamivudine tablets are contraindicated in patients with a previous hypersensitivity reaction to lamivudine. teratogenic effects pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to lamivudine during pregnancy. physicians are encouraged to register patients by calling the antiretroviral pregnancy registry at 1-800-258-4263.  risk summary available data from the antiretroviral pregnancy registry show no difference in the risk of overall major birth defects for lamivudine compared with the background rate for major birth defects of 2.7% in the us reference population of the metropolitan atlanta congenital d

Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - zidovudine 10 mg/ml - oral solution - 10 mg/ml - active: zidovudine 10 mg/ml excipient: citric acid monohydrate glycerol hydrogenated glucose syrup purified water saccharin sodium sodium benzoate strawberry flavour phl-134189 white sugar flavour da13780 - retrovir oral formulations are indicated in combination with other anti-retroviral agents for the treatment of human immunodeficiency virus (hiv) infection in adults and children.

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

kaiser foundation hospitals - lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95) - lamivudine 100 mg

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

appco pharma llc - lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95) - lamivudine 150 mg